Compound H42 inhibited ovarian cancer cell proliferation via HDAC6-mediated cyclin D1 degradation and suppressed ovarian cancer progression in nude xenograft mice, indicating compound H42 has a preclinical value in ovarian cancer therapeutics, warranting further investigation. Here, HDAC6 is linked to ovarian carcinoma.